High-deductible plans: 1.6 to 2.4 times the cost of chronic care
In 539,590 insured adults with diabetes or high blood pressure, recommended care cost $128.94 to $164.18 a year out of pocket in a high-deductible plan, against $53.89 to $100.60 in other plans.
By Gale Staff · October 17, 2026 · JAMA Network Open
Not reviewed by a clinician.

The short answer
Adults with employer insurance who stayed on guideline-recommended care for diabetes, hypertension or both paid 1.6 to 2.4 times as much out of pocket in a high-deductible plan as in another plan. For diabetes the estimate was $153.91 a year against $68.06, and the authors put the absolute gap at $63.68 to $85.85 a year, which they describe as relatively small. The cohort only includes people who actually received the recommended care, so the study cannot show what the higher price does to the people who skip it, and it is one retrospective look at 2022 to 2023 claims.
Who to see
Endocrinologist
Adults getting recommended diabetes care paid more out of pocket in a high-deductible plan; an endocrinologist can talk through your diabetes care.
Find care →What staying on recommended care costs under a high deductible
Picture an adult with diabetes and high blood pressure choosing between two employer plans at open enrollment. One is a high-deductible plan, where most costs come out of the person's pocket until the deductible is met. The other is a plan without that feature. The question that arrives next is a plain one: if the year goes exactly as the guidelines say it should, with the minimum recommended care for their conditions, how much more of it comes out of the person's own pocket in the first plan than in the second.
That is the question a retrospective cohort study in JAMA Network Open, published on 13 October 2026, set out to put a number on. Risha Gidwani and colleagues pointed out that high-deductible health plans already enroll a substantial share of privately insured Americans and are associated with people using less care, even care considered medically necessary. What was missing, they wrote, was the size of the out-of-pocket bill that evidence-based care actually carries inside those plans.
How the study was built
The team used national commercial insurance claims from 2022 and 2023. The participants were adults aged 18 to 64 with employer-sponsored insurance and a previously diagnosed case of diabetes, hypertension, or both. The detail that shapes everything after it is the entry rule: to be in the cohort, a person had to have received guideline-concordant care for their condition. The study therefore describes the price paid by people who got the recommended care, and it says nothing directly about people who did not.
The final cohort was 539,590 adults. High-deductible enrollees and everyone else differ in ways that could muddy a cost comparison, so the authors used entropy balancing, a weighting method that adjusts one group until its measured characteristics match the other. It worked on the measures the abstract reports: men were 57.9% of high-deductible enrollees and 57.8% of the others, and 45.4% of both groups were aged 55 to 64. Generalized linear models with geographic fixed effects, meaning comparisons made within the same area, then estimated the mean annual out-of-pocket cost of receiving the minimum recommended care. Data were analyzed from July 2025 to April 2026.
Three conditions, three gaps, one direction
For guideline-concordant diabetes care, the estimated annual out-of-pocket cost was $153.91 (95% confidence interval $150.18 to $157.64) in a high-deductible plan and $68.06 ($66.34 to $69.78) in a non-high-deductible plan. For hypertension care it was $128.94 ($127.25 to $130.64) against $53.89 ($53.20 to $54.58). For people with both conditions it was $164.18 ($160.93 to $167.44) against $100.60 ($98.80 to $102.39). Every difference reached P below .001.
In relative terms the authors report costs 1.6 to 2.4 times as high in the high-deductible plans. Dividing the printed figures shows where the ends of that range sit: roughly 2.4 times for hypertension, 2.3 times for diabetes, and 1.6 times for people carrying both conditions. The group with both conditions pays the most in dollars under either kind of plan, but the plan type adds the least to their bill in proportion, which is consistent with the lower-deductible plans charging more once a person has more to treat. The abstract does not give a reason, so that is a reading of the pattern and not a finding.
In absolute terms the authors report a range of $63.68 to $85.85 a year and call the difference relatively small. The upper end matches the printed diabetes figures exactly. Subtracting the printed combined-condition means gives $63.58 rather than $63.68, a ten-cent mismatch that is probably rounding or weighting, but it is the kind of thing worth noting for anyone quoting the abstract.
The caveat that sits in the entry rule
A cost study that only counts people who received care measures the price of care for the people who paid it. It cannot measure the people for whom the price, or the fear of it, meant a skipped refill or a visit never booked. Those people are absent from the denominator by design. The authors point to earlier work linking high-deductible plans to reduced use of care and describe this study as complementing it, which is the right framing: the earlier studies count who stays away, and this one counts what the people who stay in are charged.
That also means the dollar figures should not be read as what a typical enrollee with these conditions pays. They are estimates of the cost of the minimum recommended care, built from claims and weighted to represent the full sample of chronically ill persons. Real annual spending for the same person could be higher once additional visits, complications or non-recommended care are counted, and could be lower or higher depending on how a given plan handles preventive and drug benefits, which the abstract does not describe.
Why a small gap still matters
An extra $64 to $86 a year is small in dollar terms, and the authors describe the gap as relatively small. Its weight comes from how it is paid. A deductible asks for money at the point of care, in the pharmacy line or at the front desk, and a recurring condition produces that moment many times a year. A price that looks modest as an annual total can still shape a decision when it arrives in pieces for people who are already managing a long-term illness.
The authors say the findings put a number on the cost burden chronically ill patients face under different insurance arrangements, and that they complement earlier high-deductible studies of how much care people use. The estimates come from a population large enough that the confidence intervals are narrow. Whether the added cost changes what people do is a separate question, and this paper leaves it open.
What this study can't tell you
- Whether the extra cost changes behavior: the cohort only contains people who received guideline-concordant care, so anyone who skipped or delayed care because of cost is outside the study by design.
- What these people pay in total: the outcome is the out-of-pocket cost of the minimum recommended care, and the abstract does not report total yearly spending, premiums, or costs from complications or additional care.
- Whether the gap is caused by the plan type: this is a retrospective cohort, and although entropy balancing matched the groups on the measured traits the abstract lists (sex and age are the ones reported), unmeasured differences between people who choose or are offered each kind of plan could remain.
- How the result holds beyond adults aged 18 to 64 with employer coverage and a diagnosis already on record: people on other kinds of insurance, older adults and anyone newly diagnosed are not represented.
- Why the relative gap is smallest for people with both conditions: the abstract gives the figures but not an explanation, so any reason offered is a reading of the pattern.
- Who funded the study and what the full methods and limitations section says: only the abstract was read for this story, and it does not report funding or the authors' discussion of their own limits.
The Gale read
This is a paper that makes a modest claim and states it modestly. The authors measured one thing, the out-of-pocket price of staying on recommended care, and they report both the ratio and the dollar gap, which is the pairing that keeps a 2.4-times headline from sounding larger than a difference of roughly $64 to $86 a year. The confidence intervals are narrow, as they would be with 539,590 people, so the sampling error is not the concern. The concern is who is counted. By requiring that everyone in the cohort already received the recommended care, the design answers what care costs for those who get it and stays silent on those who did not, and the abstract itself does not claim otherwise. The best way to read the result is as one input to a larger question about whether cost-sharing shapes how people manage a long-term illness, a question that needs data on people who skipped care as well as people who did not. Taken alone, a retrospective claims study cannot say that the plan type caused the gap, and it should not have to.
Common questions
how much more do high deductible health plans cost for diabetes care
In this study of 539,590 adults with employer insurance, the estimated annual out-of-pocket cost of guideline-concordant diabetes care was $153.91 in a high-deductible plan and $68.06 in other plans, about 2.3 times as much. The authors put the absolute gap across all three condition groups at $63.68 to $85.85 a year, and they describe it as relatively small. The cohort only includes people who received the recommended care, so it does not capture anyone who skipped it because of cost.
do high deductible plans cost more for high blood pressure treatment
Yes, in this analysis. Guideline-concordant hypertension care cost an estimated $128.94 a year out of pocket in a high-deductible plan against $53.89 in other plans, the largest ratio in the study at roughly 2.4 times. It is a retrospective claims comparison from 2022 and 2023, balanced on measured traits such as sex and age, so it shows an association between plan type and cost and cannot prove the plan itself caused every dollar of the gap.
are high deductible health plans bad for people with chronic illness
This study does not answer that. It measured what recommended care costs people who received it, and found those costs 1.6 to 2.4 times higher in high-deductible plans, but it did not measure health outcomes or the people who went without care. The authors cite earlier research linking these plans to reduced use of care and present this paper as complementing it by quantifying the cost side, so the question of harm rests on that other work.
Sources
- 1.Gidwani R, Wagner Z, Asch SM, Yank V, Burgette L. Out-of-Pocket Costs for Chronic Illness Management in High-Deductible Health Plans. JAMA Network Open. 2026;9(10):e2638780. doi:10.1001/jamanetworkopen.2026.38780 link
1 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy
More from Gale Staff
Research
Top-Third Vitamin D Came With 19 More Minutes of Sleep a NightResearch
A Stroke Drug Beat Placebo, 69.7% to 56.3%; An Earlier Trial Did Not
Published October 17, 2026 · Gale Staff